Intermolecular : Reports Second Quarter 2019 Financial Results

SAN JOSE, Calif., Aug. 8, 2019 /PRNewswire/ -- Intermolecular, Inc. (Nasdaq: IMI), the trusted partner for advanced materials innovation, today reported results for its second quarter ended June 30, 2019.

Second Quarter of 2019 Financial Results
Revenue for the second quarter of 2019 was $4.6 million, a decrease of 31% from $6.7 million in the first quarter of 2019, and a decrease of 53% from $9.8 million in the same period a year ago. Program revenue was $4.5 million, a 30% decrease from $6.4 million in the first quarter of 2019, and a 52% decrease from $9.4 million in the same period a year ago.

Gross profit for the second quarter of 2019 was $3.2 million (69% of total revenue), a 34% decrease from $4.8 million (73% of total revenue) in the first quarter of 2019, and a 54% decrease from $6.9 million (71% of total revenue) in the same period a year ago.

Total operating expenses for the second quarter of 2019 were $8.7 million, an 18% increase from $7.4 million in the first quarter of 2019, and an increase of 30% compared to $6.7 million in the same period a year ago.

Net loss for the second quarter of 2019 totaled $(5.3) million, or $(0.11) per basic and diluted share, compared to net loss of $(2.3) million, or $(0.05) per basic and diluted share in the first quarter of 2019, and compared to net income of $0.5 million, or $0.01 per basic and diluted share in the same period a year ago.

Non-GAAP net loss, which excludes stock-based compensation expense, for the second quarter of 2019 totaled $(4.9) million, or $(0.10) per basic and diluted share, compared to non-GAAP net loss of $(1.8) million, or $(0.04) per basic and diluted share in the first quarter of 2019, and compared to non-GAAP net income of $0.7 million, or $0.01 per basic and diluted share in the same period a year ago. 

Adjusted EBITDA for the second quarter of 2019 totaled $(4.6) million, compared to an adjusted EBITDA of $(1.3) million in the first quarter of 2019 and Adjusted EBITDA of $1.8 million in the same period a year ago. 

Cash and investments totaled $23.9 million at the end of second quarter of 2019, a decrease of $3.5 million compared to $27.4 million at the end of first quarter of 2019. The company had no debt as of June 30, 2019.   

Intermolecular reports revenue, cost of revenue, gross margin, operating income (loss), net income (loss) and earnings (loss) per share in accordance with U.S. generally accepted accounting principles (GAAP) and additionally on a non-GAAP basis. A reconciliation of the non-GAAP financial measures with the most directly comparable GAAP measures, as well as a description of the items excluded from the non-GAAP measures, is included in the financial statements portion of this press release. Please refer to "Reconciliation of GAAP to Non-GAAP Financial Measures" and "Reconciliation of GAAP Net Loss to Non-GAAP Net Loss" below.

Agreement and Plan of Merger
Intermolecular will not hold an earnings call, nor provide forward guidance for the third quarter of fiscal year 2019, due to the previously announced proposed acquisition of Intermolecular by Merck KGaA, Darmstadt, Germany.

About Intermolecular, Inc.
Intermolecular^® is the trusted partner for advanced materials innovation. Advanced materials are at the core of innovation in the 21^st century for a wide range of industries including semiconductors, consumer electronics, automotive and aerospace. With its substantial materials expertise, accelerated learning and experimentation platform, and information and analytics infrastructure, Intermolecular has a ten-year track record helping leading companies accelerate and de-risk materials innovation. Learn more at www.intermolecular.com.

"Intermolecular" and the Intermolecular logo are registered trademarks; all rights reserved.

Non-GAAP Financial Measures
To supplement the financial data presented on a GAAP basis, we also disclose certain non-GAAP financial measures, which exclude the effect of stock-based compensation expense. These non-GAAP financial measures are not prepared in accordance with GAAP, do not serve as an alternative to GAAP and may be calculated differently than non-GAAP financial information disclosed by other companies. These results should only be used to evaluate our results of operations in conjunction with the corresponding GAAP measures. We believe that our non-GAAP financial information provides useful information to management and investors regarding financial and business trends relating to our financial condition and results of operations because the non-GAAP measures exclude charges that management considers to be outside of Intermolecular's core operating results. We believe that the non-GAAP measures of revenue, cost of net revenue, gross profit, gross margin, operating (loss) income, net (loss) income, Adjusted EBITDA, earnings per share and net (loss) income per share, viewed in combination with our financial results calculated in accordance with GAAP, provide investors with additional perspective and a more meaningful understanding of our ongoing operating performance. In addition, management uses these non-GAAP measures to review and assess financial performance, to determine executive officer incentive compensation and to plan and forecast performance in future periods.

Investor Contact
Bill Roeschlein
Intermolecular, Inc.
Chief Financial Officer
[e-mail]
[phone]

 

Intermolecular, Inc.
Condensed Consolidated Statements of Operations
(In thousands, except share and per share amounts, Unaudited)
		Three Months Ended June 30,								Six Months Ended June 30,
		2019				2018				2019				2018
Revenue:
Program revenue		$	4,485			$	9,365			$	10,870			$	18,621
Licensing and royalty revenue			133				437				399				856
Total revenue			4,618				9,802				11,269				19,477
Cost of revenue:
Cost of program revenue			1,437				2,856				3,255				6,231
Cost of licensing and royalty revenue			—				3				—				4
Total cost of revenue			1,437				2,859				3,255				6,235
Gross profit			3,181				6,943				8,014				13,242
Operating expenses:
Research and development			4,216				4,056				8,362				8,087
Sales and marketing			974				858				1,864				1,654
General and administrative			3,494				1,748				5,832				4,034
Total operating expenses			8,684				6,662				16,058				13,775
Income (loss) from operations			(5,503)				281				(8,044)				(533)
Other income (expenses), net
Interest income (expense), net			172				140				355				245
Other income (expense), net			(3)				75				93				162
Total other income (expense), net			169				215				448				407
Income (loss) before provision for income taxes			(5,334)				496				(7,596)				(126)
Provision for income taxes			-				-				-				1
Net income (loss)		$	(5,334)			$	496			$	(7,596)			$	(127)
Earnings (loss) per share:
Basic		$	(0.11)			$	0.01			$	(0.15)			$	(0.00)
Diluted		$	(0.11)			$	0.01			$	(0.15)			$	(0.00)
Weighted-average number of shares used in computing earnings (loss) per share:
Basic			49,758,224				49,672,739				49,757,917				49,627,584
Diluted			49,758,224				50,059,639				49,757,917				49,627,584

 

Intermolecular, Inc.
Condensed Consolidated Balance Sheets
(In thousands, Unaudited)
		As of June 30, 2019				As of December 31, 2018
ASSETS
Current assets:
Cash and cash equivalents		$	2,160			$	8,351
Short-term investments			21,753				22,098
Total cash, cash equivalents and short-term investments			23,913				30,449
Accounts receivable			1,941				3,349
Prepaid expenses and other current assets			1,004				936
Total current assets			26,858				34,734
Materials inventory			2,375				2,638
Property and equipment, net			2,809				3,432
Intangible assets, net			1,892				2,075
Right-of-use lease assets - operating			10,841				—
Other assets			503				514
Total assets		$	45,278			$	43,393
LIABILITIES AND STOCKHOLDERS' EQUITY
Current liabilities:
Accounts payable		$	112			$	760
Accrued liabilities			1,592				1,234
Accrued compensation and employee benefits			1,984				3,431
Current portion of lease obligation - operating			1,816				—
Deferred revenue			159				917
Total current liabilities			5,663				6,342
Deferred rent			—				2,667
Long term lease obligation - operating			11,832				—
Total liabilities			17,495				9,009
Stockholders' equity:
Common stock			50				50
Additional paid-in capital			216,974				216,034
Accumulated other comprehensive income (loss)			28				(27)
Accumulated deficit			(189,269)				(181,673)
Total stockholders' equity			27,783				34,384
Total liabilities and stockholders' equity		$	45,278			$	43,393

 

Intermolecular, Inc.
Condensed Consolidated Statements of Cash Flows
(In thousands, Unaudited)
		Six Months Ended June 30,
		2019				2018
Cash flows from operating activities:
Net loss		$	(7,596)			$	(127)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation, amortization and accretion			1,123				2,693
Amortization expense - Right of use lease assets operating			787				—
Stock-based compensation			935				482
Loss on disposal of property and equipment			2				—
Changes in operating assets and liabilities:
Accounts receivable			1,408				4,074
Prepaid expenses and other assets			(57)				393
Materials inventory			291				(134)
Accounts payable			(520)				(750)
Accrued and other liabilities			(1,634)				(67)
Deferred revenue			(759)				(633)
Net cash (used in) provided by operating activities			(6,020)				5,931
Cash flows from investing activities:
Purchase of investments			(13,804)				(19,367)
Redemption of investments			14,202				12,010
Purchase of property and equipment			(574)				(489)
Net cash used in investing activities			(176)				(7,846)
Cash flows from financing activities:
Proceeds from exercise of common stock options			5				172
Net cash provided by financing activities			5				172
Net decrease in cash and cash equivalents			(6,191)				(1,743)
Cash and cash equivalents at beginning of period			8,351				6,090
Cash and cash equivalents at end of period		$	2,160			$	4,347

 

Intermolecular, Inc.
Reconciliation of GAAP to Non-GAAP Financial Measures
(In thousands, except per share amounts and percentages, Unaudited)
		Three Months Ended June 30,								Six Months Ended June 30,
		2019				2018				2019				2018
GAAP cost of net revenue		$	1,437			$	2,859			$	3,255			$	6,235
Stock-based compensation expense (a)			(36)				(39)				(81)				(92)
Non-GAAP cost of net revenue		$	1,401			$	2,820			$	3,174			$	6,143
GAAP gross profit		$	3,181			$	6,943			$	8,014			$	13,242
Stock-based compensation expense (a)			36				39				81				92
Non-GAAP gross profit		$	3,217			$	6,982			$	8,095			$	13,334
As a percentage of net revenue:
GAAP gross margin			68.9	%			70.8	%			71.1	%			68.0	%
Non-GAAP gross margin			69.7	%			71.2	%			71.8	%			68.5	%
GAAP operating income (loss)		$	(5,503)			$	281			$	(8,044)			$	(533)
Stock-based compensation expense (a):
- Cost of net revenue			36				39				81				92
- Research and development			120				59				233				114
- Sales and marketing			57				21				110				51
- General and administrative			259				93				511				225
Non-GAAP operating income (loss)		$	(5,031)			$	493			$	(7,109)			$	(51)
GAAP net income (loss)		$	(5,334)			$	496			$	(7,596)			$	(127)
Stock-based compensation expense (a)			472				212				935				482
Non-GAAP net income (loss)		$	(4,862)			$	708			$	(6,661)			$	355
GAAP net income (loss)		$	(5,334)			$	496			$	(7,596)			$	(127)
Interest (income) expense, net			(172)				(140)				(355)				(245)
Provision for taxes			—				—				—				1
Depreciation, amortization, impairments and accretion			458				1,270				1,123				2,693
Stock-based compensation expense (a)			472				212				935				482
Adjusted EBITDA		$	(4,576)			$	1,838			$	(5,893)			$	2,804
Shares used in computing basic and diluted earnings per share:
Basic			49,758,224				49,672,739				49,757,917				49,627,584
Diluted			49,758,224				50,059,639				49,757,917				49,627,584
GAAP earnings (loss) per share:
Basic		$	(0.11)			$	0.01			$	(0.15)			$	(0.00)
Diluted		$	(0.11)			$	0.01			$	(0.15)			$	(0.00)
Non-GAAP earnings (loss) per share:
Basic		$	(0.10)			$	0.01			$	(0.13)			$	0.01
Diluted		$	(0.10)			$	0.01			$	(0.13)			$	0.01

(a)	Stock-based compensation reflects expense recorded relating to stock-based awards. The Company excludes this item when it evaluates the continuing operational performance of the Company, as management believes this provides it a meaningful understanding of its core operating performance.

 

 

View original content to download multimedia:http://www.prnewswire.com/news-releases/intermolecular-reports-second-quarter-2019-financial-results-300899032.html

SOURCE Intermolecular, Inc.